Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared on X:
“Press release Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer | Exelixis, Inc.”